Rj. Mathvink et al., Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide, J MED CHEM, 43(21), 2000, pp. 3832-3836
As part of our investigation into the development of orally bioavailable be
ta (3) adrenergic receptor agonists, we have identified a series of pyridyl
ethanolamine analogues possessing a substituted thiazole benzenesulfonamide
pharmacophore that are potent human beta (3) agonists with excellent selec
tivity against other human beta receptor subtypes. Several of these compoun
ds also exhibited an improved pharmacokinetic profile in dogs. For example,
thiazole sulfonamide 2e (R = 4-F3C-C6H4) is a potent full beta (3) agonist
(EC50 = 3.6 nM, 94% activation) with >600-fold selectivity over the human
beta (1) and beta (2) receptors, which also displays good oral bioavailabil
ity in several mammalian species, as well as an extended duration of action
.